Loading news...
GE HealthCare Technologies (NASDAQ: GEHC) reported fourth-quarter and full-year 2025 results that management said came in above expectations, driven by strength in pharmaceutical diagnostics and steady demand for capital equipment in the U.S. and EMEA. Executives also outlined a 2026 outlook that assumes continued healthy end markets while taking a cautious stance on China and anticipating
GE HealthCare Technologies delivered strong Q4 2025 results, with revenue and adjusted EPS exceeding analyst expectations and robust segmental growth. GEHC remains a 'buy' as shares are attractively valued relative to peers, despite recent outperformance and an absolute valuation near fair value. Key growth drivers include the Imaging and Pharmaceutical Diagnostics segments, innovation in cloud-first imaging, and strategic acquisitions like Intelerad.
Revenue: $5.7 billion in Q4, 4.8% organic growth year-over-year.Product Revenue Growth: 7.9% in Q4.Service Revenue Growth: 5.5% in Q4.Orders Growth: 2% in Q4.B
GE HealthCare Technologies Inc. (GEHC) Q4 2025 Earnings Call Transcript
GE HealthCare (NASDAQ: GEHC) on Wednesday reported adjusted earnings of $1.44 per share, beating the consensus of $1.40.
GEHC tops Q4 EPS and revenue estimates as Imaging and PDx drive growth, but net margin slides on tariffs and product mix.
The headline numbers for GE HealthCare (GEHC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago.
GE HealthCare on Wednesday forecast annual profit above Wall Street estimates, betting on robust demand for its diagnostic and imaging devices.
Wednesday, GE HealthCare reported fourth-quarter earnings per share of $1.44 from sales of $5.7 billion. Wall Street was looking for earnings per share of $1.40 from sales of $5.6 billion.
GE HealthCare Technologies said profit fell in the fourth quarter, despite higher revenue, as the company continues to operate in what Chief Executive Peter Arduini called a dynamic macroeconomic environment.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. GE HealthCare President and CEO Peter Arduini said, “In our third year as a public company, we've made great strides executing our strategy focused on precision care, growth acceleration, and business optimization. We delivered a strong quarter and year with growth in Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions. This.
GE HealthCare's Allia Moveo wins FDA and CE clearance, enabling commercialization of a mobile C-arm with AI guidance, compact design and early global installs.
GEHC heads into fourth-quarter earnings with steady demand and strong product momentum, though tariffs and investments may keep margins in focus.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for GE HealthCare (GEHC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company's bold innovations first unveiled at the Radiological Society of North America's (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and.
Bank of New York Mellon Corp lowered its stake in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 1.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,194,405 shares of the company's stock after selling 62,766 shares during the period. Bank of
GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) is expected to release its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect GE HealthCare Technologies to post earnings of $1.43 per share and revenue of $5.6021 billion for the quarter. Individuals can find conference call details on the company's upcoming Q4
Anchor Capital Advisors LLC increased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 9.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 693,307 shares of the company's stock after purchasing an additional